Retinal pigment epithelial tear following intravitreal injection of bevacizumab (Avastin).
OBJECTIVE
To report one case of retinal pigment epithelium tear following intravitreal bevacizumab injection for neovascular age-related macular degeneration.


METHODS
A 59-year-old patient presented with occult choroidal neovascularization associated with a serous pigment epithelial detachment secondary to age-related macular degeneration. The patient was treated with an intravitreal injection of bevacizumab.


RESULTS
The patient developed a retinal pigment epithelium tear 60 days following the intravitreal injection.


CONCLUSIONS
This report describes the development of retinal pigment epithelium tear after intravitreal bevacizumab injection. Future studies should be performed to evaluate which subtypes of lesions are most susceptible to this potential devastating visual complication.
Nicolò
M
M
Department of Neuroscience, Ophthalmology and Genetics, University Eye Clinic and Ist. Biosanitas, Genova, Italy. massimonicolo@occhioallaretina.it
Ghiglione
D
D
Calabria
G
G
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000150:complications / Q000188:drug therapy; D003937:Diagnosis, Differential; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005654:Fundus Oculi; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000150:complications / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010857:Pigment Epithelium of Eye / Q000187:drug effects / Q000473:pathology*; D012163:Retinal Detachment / Q000188:drug therapy / Q000209:etiology; D012167:Retinal Perforations / Q000139:chemically induced* / Q000175:diagnosis; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab